Evidence map›Paper›PMID 40061175›Full record

ArticleBlood cell therapy2025

Eltrombopag Enhances Recovery from Cytopenias Due to Poor Graft Function after Hematopoietic Cell Transplantation.

Khalid Halahleh, Maram Al-Ya'Goub, Mohamad Ma'koseh, Rozan Al-Far, Waleed Da'na, Rula Al-Najjar Pharm, Ayat Taqash, Isra Muradi, Maher Sughayer, Husam Abu-Jazar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cell therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Khalid HalahlehDepartment of Internal Medicine, Medical Oncology Section, Bone Marrow Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
Maram Al-Ya'GoubDepartment of Internal Medicine, Medical Oncology Section, King Hussein Cancer Center, Amman, Jordan.
Mohamad Ma'kosehDepartment of Internal Medicine, Medical Oncology Section, Bone Marrow Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
Rozan Al-FarDepartment of Internal Medicine, Medical Oncology Section, Bone Marrow Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
Waleed Da'naDepartment of Internal Medicine, Medical Oncology Section, Bone Marrow Transplantation Program, King Hussein Cancer Center, Amman, Jordan.
Rula Al-Najjar PharmDepartment of Pharmacy, King Hussein Cancer Center, Amman, Jordan.
Ayat TaqashResearch Office, Biostatistics Unit, King Hussein Cancer Center, Amman, Jordan.
Isra MuradiDepartment of Laboratory Sciences, Al-Ahliyya Amman University, Al-Salt, Jordan.
Maher SughayerDepartment of Pathology, King Hussein Cancer Center, Amman, Jordan.
Husam Abu-JazarDepartment of Internal Medicine, Medical Oncology Section, Bone Marrow Transplantation Program, King Hussein Cancer Center, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Poor graft function (PrGF) is a serious complication of allogeneic hematopoietic cell transplantation (allo-HCT), and current therapies are only partially effective. Eight published reports on the effect of eltrombopag on PrGF showed encouraging results. This study aimed to assess the safety and efficacy of eltrombopag for the treatment of PrGF after allo-HCT. Methods: A retrospective study was conducted on 23 patients with PrGF following allo-HCT at the King Hussein Cancer Center (KHCC), Amman, Jordan between January 2013 and December 2023. The patient-, disease-, and transplant-related characteristics were obtained from the KHCC-BMT database. Results: The median age was 47 years (range, 26-68 years), and 13 patients were female. Fourteen patients received reduced-intensity conditioning, and 14 donors were human-leukocyte antigen (HLA) -identical siblings. Median hemoglobin (Hb) concentration pre-eltrombopag administration was 8.5 g/dL (range: 6-14.2 g/dL), granulocytes 7.1 × 10 Conclusion: Eltrombopag improved peripheral blood counts in patients with PrGF following allo-HCT. Thus, response to eltrombopag was predictable and has a significant effect on survival.

Indexed as

allogeneic hematopoietic cell transplantationcytopeniaKing Hussein Cancer Centerpoor graft function

Identifiers

PMID40061175
PMCPMC11883521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.